Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central anxious program, conolidine modulates alternate molecular targets. A Science Advances review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://margaretz764qcv7.wikirecognition.com/user